Company: SXTPW
Filing Date: 2025-07-16
Form Type: 424B4
Source: 0001213900-25-064472
Chunk: 29

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-16
Form: 424B4
Chunk 29
---
 patent applications for research, clinical, teaching, or other non-commercial purposes. In exchange for the license
granted by Yale to us, we agree to pay Yale a royalty of 2% on net sales of licensed products covering the licensed patents if the licensed
product is branded for treatment of babesiosis and a royalty of 1% on net sales of licensed products covering the licensed patents if
the licensed product is not specifically branded for treatment of babesiosis.

Corporate Structure

60 Degrees Pharmaceuticals, Inc. is a Delaware
corporation that was incorporated on June 1, 2022.

On June 1, 2022, 60 Degrees Pharmaceuticals, LLC,
a District of Columbia limited liability company (“60P LLC”), entered into the Agreement and Plan of Merger with 60 Degrees
Pharmaceuticals, Inc., pursuant to which 60P LLC merged into 60 Degrees Pharmaceuticals, Inc. The value of each outstanding member’s
membership interest in 60P LLC was correspondingly converted into common stock of 60 Degrees Pharmaceuticals, Inc., par value $0.0001
per share, with a cost-basis equal to $300.00 per share.

Our majority-owned subsidiary, 60P Australia Pty
Ltd, an Australian proprietary company limited by shares (“60P Australia”), was formed and registered in Queensland on December
3, 2013, and conducts operations in Australia.

<div align='center'>11</div>

60P Australia previously solely owned a Singaporean
subsidiary company, 60P Singapore Pte. Ltd., which dissolved at our election in the second quarter of 2022.

On February 24, 2025, we effected a reverse stock
split of our common stock at a ratio of 1-for-5.

Going Concern

Our independent auditors have issued a report
raising substantial doubt of our ability to continue as a going concern. We anticipate that we will require additional capital to continue
as a going concern and expand our operations in accordance with our current business plan.

Suppliers

We have quality and contract manufacturing agreements
relating to Arakoda in place with Piramal Enterprises Limited (API, tablets) and PCI Pharma Services (secondary packaging) (“PCI”)
and supply/quality/pharmacovigilance agreements in place with Biocelect Pty Ltd, Scandinavian Biopharma, and Knight Therapeutics Inc.
(to allow supply of Arakoda/Kodatef to Australia, Europe and Canada/Israel/Latin America and Russia